Trump Demands Transparency from COVID-19 Drug Makers Amid FDA Restrictions

President Trump demands Pfizer and other COVID-19 drug makers to justify their success and disclose results more openly, criticizing the companies for not publicly showing extraordinary results. Trump's push for transparency comes after the FDA introduced new restrictions on COVID-19 vaccine eligibility, and amid a turbulent time for the nation's health agencies. Leading vaccine manufacturers like Pfizer and Moderna have faced sharp stock declines this year.

President Donald Trump has called for pharmaceutical companies to disclose more data on the success rates of their COVID-19 drugs, criticizing them for not publicly sharing what he described as "extraordinary" results. This demand comes amidst a backdrop of new FDA restrictions on COVID-19 vaccine eligibility and ongoing turmoil within the nation's health agencies.

In a Truth Social post on Monday, Trump expressed skepticism about why the data has not been released to the public, despite the division over the success of COVID-19 drugs. He specifically mentioned Pfizer, Moderna, and other pharmaceutical companies, demanding they release their data to the CDC and the public [1].

Pfizer responded to Trump's call for transparency by releasing a collection of more than 200 press releases and statements and 27 peer-reviewed publications with data dating back to early 2020. Pfizer CEO Albert Bourla stated that Trump's call for transparency is welcome and that the company remains deeply committed to this principle [2]. Bourla also acknowledged the success of Operation Warp Speed under Trump's leadership, noting that American innovations have saved millions of lives worldwide [2].

Moderna has also responded to Trump's post by compiling previously disclosed research and findings on its website. The company praised Operation Warp Speed for its role in accelerating vaccine development, manufacturing, and distribution [3].

The demand for transparency comes at a time when leading vaccine manufacturers like Pfizer and Moderna have faced sharp stock declines this year. The companies have defended their vaccines, pointing to the success of Operation Warp Speed and the significant impact of their innovations on public health [3].

The FDA's recent decision to introduce new restrictions on COVID-19 vaccine eligibility has added to the ongoing turmoil within the nation's health agencies. Health and Human Services Secretary Robert F. Kennedy Jr. announced last week that the vaccination would be approved for adults 65 and older as well as for kids and adults with at least one medical condition that puts them at risk of severe illness [1].

The demand for transparency is likely to continue, with both Pfizer and Moderna pledging to release additional information and studies in the coming days and weeks. As the debate over vaccine policy and public health directives grows, investors and financial professionals will be closely watching the companies' responses and the potential impact on their stock prices.

References:
[1] https://www.nbcnews.com/health/health-news/trump-demands-pharmaceutical-companies-release-covid-drug-success-rate-rcna228397
[2] https://mezha.net/eng/bukvy/pfizer-shares-covid-19-vaccine-data-after-trump-s-transparency-call/
[3] https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-moderna-defend-covid-vaccine-effectiveness-after-trump-remarks-2025-09-03/